Bo-Wen Cui

Mechanisms and Clinical Breakthroughs of Bispecific Antibody–Drug Conjugates (BsADCs)- Dual‑Targeting Strategies Exemplified by EGFR/HER3

Cancer remains a major burden, with conventional and single-target ADC therapies limited by toxicity, heterogeneity, and resistance. The development of bispecific ADCs (BsADCs) is a product of the latest developments in this field, but most of these drugs are still at an early stage of design and clinical evaluation. I...